59 related articles for article (PubMed ID: 15341084)
1. [Antiplatelet effects of glycoproteins IIb-IIIa antagonist monafram].
Mazurov AV; Pevzner DV; Vlasik TN; Ruda MIa
Ross Fiziol Zh Im I M Sechenova; 2004 May; 90(5):586-99. PubMed ID: 15341084
[TBL] [Abstract][Full Text] [Related]
2. Safety, inhibition of platelet aggregation and pharmacokinetics of Fab'2 fragments of the anti-glycoprotein IIb-IIIa monoclonal antibody FRaMon in high-risk coronary angioplasty.
Mazurov AV; Pevzner DV; Antonova OA; Byzova TV; Khaspekova SG; Semenov AV; Vlasik TN; Samko AN; Staroverov II; Ruda MY
Platelets; 2002 Dec; 13(8):465-77. PubMed ID: 12487780
[TBL] [Abstract][Full Text] [Related]
3. [Inhibition of thrombocyte aggregation by F(ab')2-fragments of monoclonal antibodies FraMon (CRC64) to glycoproteins IIb-IIIa].
Mazurov AV; Pevzner DV; Khaspekova SG; Dudnik OA; Byzova TV; Vlasik TN; Bakharev VN; Pistsov MIu; Staroverov II; Ruda MIa
Ter Arkh; 2001; 73(9):66-73. PubMed ID: 11642086
[TBL] [Abstract][Full Text] [Related]
4. [Glycoprotein IIb-IIIa antagonist Monafram in primary angioplasty of patients with acute coronary syndrome without st segment elevation].
Pevzner DV; Staroverov II; Samko AN; Frolova NS; Mazurov AV; Ruda MY
Kardiologiia; 2010; 50(6):22-6. PubMed ID: 20659023
[TBL] [Abstract][Full Text] [Related]
5. Effects of platelet glycoprotein IIb-IIIa number and glycoprotein IIIa Leu33Pro polymorphism on platelet aggregation and sensitivity to glycoprotein IIb-IIIa antagonists.
Sirotkina OV; Khaspekova SG; Zabotina AM; Shimanova YV; Mazurov AV
Platelets; 2007 Nov; 18(7):506-14. PubMed ID: 17957566
[TBL] [Abstract][Full Text] [Related]
6. [Results of clinical trials of a novel glycoprotein IIb-IIIa antagonist framon in high-risk coronary angioplasty].
Mazurov AV; Pevzner DV; Staroverov II; Samko AN; Antonova OA; Ivanov VA; Abugov SA; Gontuar MG; Chestukhin VV; Vlasik TN; Ruda MIa
Kardiologiia; 2005; 45(5):4-12. PubMed ID: 16007042
[TBL] [Abstract][Full Text] [Related]
7. Ability of different glycoprotein IIb-IIIa ligands to support platelet aggregation induced by activating antibody CRC54.
Naimushin YA; Mazurov AV
Biochemistry (Mosc); 2005 Jul; 70(7):782-9. PubMed ID: 16097942
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacodynamics, safety, and clinical effects of a novel glycoprotein IIb/IIIa antagonist framon during high risk coronary angioplasty].
Mazurov AV; Pevzner DV; Semenov AV; Antonova OA; Dudnik OA; Khaspekova SG; Vlasik TN; Samko AN; Staroverov II; Ruda MIa
Kardiologiia; 2002; 42(6):8-17. PubMed ID: 12494124
[TBL] [Abstract][Full Text] [Related]
9. Role of glycoprotein IIb-IIIa (alpha IIb beta 3-integrin) in stimulation of secretion from platelet granules.
Naimushin YA; Mazurov AV
Biochemistry (Mosc); 2003 Feb; 68(2):209-16. PubMed ID: 12693968
[TBL] [Abstract][Full Text] [Related]
10. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.
Kleiman NS; Raizner AE; Jordan R; Wang AL; Norton D; Mace KF; Joshi A; Coller BS; Weisman HF
J Am Coll Cardiol; 1995 Dec; 26(7):1665-71. PubMed ID: 7594101
[TBL] [Abstract][Full Text] [Related]
11. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
[TBL] [Abstract][Full Text] [Related]
12. Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys.
Kaku S; Kawasaki T; Hisamichi N; Sakai Y; Taniuchi Y; Inagaki O; Yano S; Suzuki K; Terazaki C; Masuho Y; Satoh N; Takenaka T; Yanagi K; Ohshima N
Thromb Haemost; 1996 Apr; 75(4):679-84. PubMed ID: 8743199
[TBL] [Abstract][Full Text] [Related]
13. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A
Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395
[TBL] [Abstract][Full Text] [Related]
14. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
[TBL] [Abstract][Full Text] [Related]
15. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion.
Quinn MJ; Murphy RT; Dooley M; Foley JB; Fitzgerald DJ
J Pharmacol Exp Ther; 2001 May; 297(2):496-500. PubMed ID: 11303035
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris.
Gold HK; Gimple LW; Yasuda T; Leinbach RC; Werner W; Holt R; Jordan R; Berger H; Collen D; Coller BS
J Clin Invest; 1990 Aug; 86(2):651-9. PubMed ID: 2384607
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamic effects of a new antibody glycoprotein IIb/IIIa inhibitor (YM337) in healthy subjects.
Harder S; Kirchmaier CM; Krzywanek HJ; Westrup D; Bae JW; Breddin HK
Circulation; 1999 Sep; 100(11):1175-81. PubMed ID: 10484537
[TBL] [Abstract][Full Text] [Related]
18. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.
Cuisset T; Frere C; Quilici J; Morange PE; Mouret JP; Bali L; Moro PJ; Lambert M; Alessi MC; Bonnet JL
JACC Cardiovasc Interv; 2008 Dec; 1(6):649-53. PubMed ID: 19463379
[TBL] [Abstract][Full Text] [Related]
19. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
Rossi F; Rossi E; Pareti FI; Colli S; Tremoli E; Gallo L
Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
[TBL] [Abstract][Full Text] [Related]
20. Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial.
Marmur JD; Mitre CA; Barnathan E; Cavusoglu E
Am Heart J; 2006 Nov; 152(5):876-81. PubMed ID: 17070148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
